Navidea biopharmaceuticals terminates stock purchase agreement

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has terminated the stock purchase agreement that was executed on august 30, 2020. on august 30, 2020, the company entered into a stock purchase agreement with each of the investors named therein (the “investors”), pursuant to which the investors agreed to purch
NAVB Ratings Summary
NAVB Quant Ranking